News

The focus of the cooperative R&D agreement (CRADA) is heat shock protein 90 (Hsp90), a target of considerable current scientific interest because of its potential pathophysiological role in

Rambazole is a novel retinoic acid metabolism-blocking agent (RAMBA). A review of initial phase IIa trial data from ten patients with moderate to severe psoriasis demonstrated a reduction

In a recent exploratory phase IIa study, Miraxion (formerly referred to as LAX-101c) was used as monotherapy in 77 patients with a new episode of depression in a

The phase III trial is designed to determine the ability of Flurizan (MPC-7869) to alter the course of cognitive decline and behavioral change in patients with Alzheimer’s disease.

The Bilive production license has now been issued by the SFDA and sales of the vaccine will commence in China shortly. This is the first combined inactivated hepatitis

The study shows that when US and European patients receive health information on how to manage their condition, nearly two thirds make proactive changes in their behavior based

Safinamide was also found to be well tolerated and did not exhibit any clinically relevant side-effects in patients with restless legs syndrome (RLS), a neurological disorder characterized by

AstraZeneca launched Entocort EC (budesonide) capsules in November 2001. In November 2004, Prometheus entered into an agreement with AstraZeneca for the marketing, sales and distribution of Entocort EC,

The phase I/IIa, open-label, dose-escalation clinical trial is being conducted at three leading oncology centers in the US. It will include approximately 30 patients with colon, stomach or